What is NXL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NXL?

P/E (TTM) is n/a and 52-week range is $2.38 to $50.70 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NXL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NXL?

The company profile lists revenue (TTM) near $227K, net income (TTM) near $-938M, EPS (TTM) near $-0.47 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Nexalin Technology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Houston, Texas, US, 22M shares outstanding, ISIN US65345B2016 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Free AI scores & summaries library

Nexalin Technology Inc

$NXL

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$2.32

-5.31%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Employees

Website

nexalin.com

IPO

2022-09-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)